SC to hear plea against Ranbaxy on Jun 24

Updated - November 16, 2021 10:21 pm IST

Published - June 17, 2013 04:47 pm IST - New Delhi

A petition seeking probe against Ranbaxy Laboratories Ltd for allegedly manufacturing and selling adulterated medicines. File photo: P.V. Sivakumar

A petition seeking probe against Ranbaxy Laboratories Ltd for allegedly manufacturing and selling adulterated medicines. File photo: P.V. Sivakumar

Supreme Court will hear on June 24 a petition seeking probe against Ranbaxy Laboratories Ltd for allegedly manufacturing and selling adulterated medicines.

A bench of justices A.K. Patnaik and Ranjan Gogoi on Monday agreed to hear the PIL after the petitioner, advocate M.L. Sharma pleaded for an urgent hearing in the case.

The case was earlier heard by a different vacation bench which had on June 10 asked Sharma to substantiate his “unfounded allegations” that the Indian pharma major was allegedly manufacturing and selling adulterated medicines. He, thereafter, filed an additional affidavit in the case.

The PIL alleged that the company has been fined $500 million by the US Food and Drug Administration (USFDA) for making and selling “adulterated” drugs. It also sought sealing of all its manufacturing units here, including those in Paonta Sahib in Himachal Pradesh and Dewas in Madhya Pradesh.

The petitioner alleged that despite Ranbaxy pleading guilty to supplying adulterated drugs in the US and it being fined such a huge amount, the Centre has not taken any action to prohibit or ban the drugs made by the company.

He also sought action against Indian drug regulator, Central Drug Standards Control Organisation (CDSCO), for permitting Ranbaxy to sell drugs in India, especially in the wake of the results of the USFDA probe against the company.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.